168 related articles for article (PubMed ID: 31486373)
1. Medical crowdfunding to access CAR T-cell therapy.
Ho LD; Oso SO; Levine AD
Lancet Oncol; 2019 Aug; 20(8):1062-1064. PubMed ID: 31486373
[No Abstract] [Full Text] [Related]
2. CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Chong EA; Levine BL; Grupp SA; Davis MM; Siegel DL; Maude SL; Gladney WL; Frey NV; Porter DL; Hwang WT; Chong ER; June CH; Schuster SJ
Blood; 2019 Nov; 134(21):1873-1875. PubMed ID: 31554634
[No Abstract] [Full Text] [Related]
3. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
4. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):529-536. PubMed ID: 31422712
[No Abstract] [Full Text] [Related]
5. Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
Corneau A; Parizot C; Cherai M; Todesco E; Blanc C; Litvinova E; Nguyen S; Roos-Weil D; Guihot A; Norol F
Br J Haematol; 2021 Aug; 194(4):788-792. PubMed ID: 34041740
[No Abstract] [Full Text] [Related]
6. What's in Your CART? Clinical insights on challenges in mononuclear cell collection for CAR-T therapy.
Annen K; Zubair A; Schwartz E; Schwartz J; Szczepiorkowski ZM
J Clin Apher; 2020 Jun; 35(3):234-235. PubMed ID: 32186782
[No Abstract] [Full Text] [Related]
7. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
9. [Research progress of CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
Yang JJ; Sang W; Xu KL
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):849-852. PubMed ID: 31665867
[TBL] [Abstract][Full Text] [Related]
10. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia.
Turazzi N; Fazio G; Rossi V; Rolink A; Cazzaniga G; Biondi A; Magnani CF; Biagi E
Br J Haematol; 2018 Sep; 182(6):939-943. PubMed ID: 28832950
[No Abstract] [Full Text] [Related]
11. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cell therapy: practical guide to routine laboratory monitoring.
Selim AG; Minson A; Blombery P; Dickinson M; Harrison SJ; Anderson MA
Pathology; 2021 Apr; 53(3):408-415. PubMed ID: 33685719
[TBL] [Abstract][Full Text] [Related]
13. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
Chong EA; Ruella M; Schuster SJ;
N Engl J Med; 2021 Feb; 384(7):673-674. PubMed ID: 33596362
[No Abstract] [Full Text] [Related]
15. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
16. Timing of CAR-T therapy in follicular lymphoma.
Alhaj Moustafa M
Expert Rev Anticancer Ther; 2023 Apr; 23(4):347-349. PubMed ID: 36825538
[No Abstract] [Full Text] [Related]
17. Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy.
Guha-Thakurta N; Wierda WG
Neurology; 2018 Oct; 91(18):843. PubMed ID: 30373920
[No Abstract] [Full Text] [Related]
18. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
19. CAR T cells for infection, autoimmunity and allotransplantation.
Maldini CR; Ellis GI; Riley JL
Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
[TBL] [Abstract][Full Text] [Related]
20. [Neurotoxicities Associated with CAR-T Cell Therapy].
Takao M
Brain Nerve; 2021 Jan; 73(1):47-58. PubMed ID: 33361513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
